International Study for Treatment of High Risk Childhood Relapsed ALL 2010

PHASE2RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
DRUG

Bortezomib

Patients randomised to the HR-B arm receive induction, consolidation with the modified ALL R3 protocol. In this arm, patients are randomized to receive Bortezomib together with the ALL R3 protocol during induction. Administration of Bortezomib: 1.3 mg/m2 as intravenous bolus or subcutaneously (SC, at the discretion of the treating physician) on days 1 and 4 of weeks 1 and 3.

Trial Locations (15)

1020

RECRUITING

Hòpital Universitaire des Enfants Reine Fabiola, Brussels

1090

RECRUITING

St. Anna Kinderkrebsforschung, CCRI, Vienna

2100

NOT_YET_RECRUITING

Copenhagen University Hospital (Rigshospitalet), Copenhagen

3168

RECRUITING

Australian & New Zealand Childhood Hematology & Oncology Group, Clayton

17176

NOT_YET_RECRUITING

University Hospital Stockholm, Stockholm

50354

RECRUITING

Dpt. SCT and Hematology/Oncology University Wroclaw, Wroclaw

64239

RECRUITING

Tel Aviv Sourasky Medical Centre, Tel Aviv

Unknown

RECRUITING

University Hospital Motol, Prague

RECRUITING

CHU Nice, Nice

RECRUITING

Prinses Máxima Centrum, Lundlaan, Utrecht

NOT_YET_RECRUITING

Instituto Português de Oncologia de Lisboa, Lisbon

SF-20520

RECRUITING

Turku University Central Hospital, Turku

00165

RECRUITING

Ospedale Pediatrico Bambino Gesù, Roma

0027

NOT_YET_RECRUITING

Oslo University Hospital, Oslo

M13 9WL

NOT_YET_RECRUITING

Royal Manchester Children's Hospital, Manchester

All Listed Sponsors
collaborator

Australian & New Zealand Children's Haematology/Oncology Group

OTHER

collaborator

St. Anna Kinderkrebsforschung, CCRI (co-sponsor, Austria)

UNKNOWN

collaborator

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

collaborator

University Hospital Motol (Co-Sponsor Czech Republic)

UNKNOWN

collaborator

Copenhagen University Hospital, Rigshospitalet (co-sponsor, Denmark)

UNKNOWN

collaborator

Turku University Central Hospital (co-sponsor, Finland)

UNKNOWN

collaborator

Centre Hospitalier Universitaire de Nice

OTHER

collaborator

Our Lady's Chilrden's Hospital (Co-Sponsor Ireland)

UNKNOWN

collaborator

Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel)

UNKNOWN

collaborator

Ospedale Pediatrico Bambino (co-sponsor, Italy)

UNKNOWN

collaborator

Prinses Máxima Centrum (Co-Sponsor Netherlands)

UNKNOWN

collaborator

Oslo University Hospital (co-sponsor, Norway)

UNKNOWN

collaborator

Medical University of Wroclaw (Co-Sponsor Poland)

UNKNOWN

collaborator

Instituto Português de Oncologia de Lisboa (co-sponsor, Portugal)

UNKNOWN

collaborator

Karolinska University Hospital Stockholm (co-sponsor, Sweden)

UNKNOWN

collaborator

Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain)

UNKNOWN

collaborator

University Children's Hospital, Zurich

OTHER

collaborator

Central Manchester University Hospitals NHS Foundation Trust (co-sponsor, UK)

UNKNOWN

lead

Charite University, Berlin, Germany

OTHER